Skip to main content
Racial and Socioeconomic Disparities in the CLL Community Oncology Setting With Ira Zackon, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial a...
Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study With Sabarish Ayyappan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 s...
Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL With Jon Arnason, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL: Jon Arnason, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Jon Arnason, MD, a Lymphoma Clinical Trial Specialist at Beth Israel Deaconess Medical Center, to discuss his abstract and pre...
Guiding Dietary Choices During Multiple Myeloma Treatment With Richa Parikh, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Guiding Dietary Choices During Multiple Myeloma Treatment: Richa Parikh, MD In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.  
Highlights of Multiple Myeloma Research Presented at ASH With Urvi Shah, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Highlights of Multiple Myeloma Research Presented at ASH 2023: Urvi Shah, MD At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment!  
Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma With Swetha Kambhampati, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD At the recent American Society of Hematology (ASH) Annual Meeting, Swetha Kambhampati, an Assistant Professor in the Division of Lymphoma at City of Hope, sat down with Oncology Data Advisor to further discuss her pr...
Exploring Revumenib for KMT2-Rearranged Acute Leukemias in the AUGMENT Trial With Ibrahim Aldoss, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring Revumenib for KMT2-Rearranged Acute Leukemias in the AUGMENT Trial: Ibrahim Aldoss, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ibrahim Aldoss, MD, an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantati...
Managing Acute Leukemias and Lymphomas When Patients Stay Local With Dipti Patel-Donnelly, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Managing Acute Leukemias and Lymphomas When Patients Stay Local: Dipti Patel-Donnelly, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Dipti Patel-Donnelly, a Medical Oncology at Virginia Cancer Specialists, hosted a session highlighting how to optimize management when patients with hema...
Exploring Acalabrutinib Plus or Minus Obinutuzumab for CLL in the ELEVATE-TN Study With Jeff Sharman, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long...
Improving End-of-Life Care for Patients With Acute Myeloid Leukemia Receiving Non-Curative Therapy: Richa Thakur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving End-of-Life Care for Patients With AML Receiving Non-Curative Therapy: Richa Thakur, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Dr. Richa Thakur, OncData Fellows Forum member and Hematology/Oncology Fellow at Northwell Health, discusses her poster presentation on ...
Improving Quality of Life in Multiple Myeloma Through Bortezomib Dose Reduction With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving QOL in Multiple Myeloma With Bortezomib Dose Reduction: Rahul Banerjee and Gurbakhash Kaur At the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Rahul Banerjee, Editor in Chief of Oncology Data Advisor, sat down with Dr. Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas (UT) Southwestern Medical Center, to discuss their abstract about real-world dosing and prescribing patterns of bortezomib in newly diagnosed multiple myeloma. Dr. Banerjee and Dr. Kaur debate the pros and cons of once- versus twice-weekly dosing of bortezomib, its impact on tolerability and outcomes, and changes in trial design that are needed to make once-weekly dosing a new standard in clinical practice.  
Real-World Outcomes of Brexucabtagene Autoleucel for B-Cell ALL With Evandro Bezerra, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Real-World Outcomes of Brexuctabtagene Autoleucel for B-Cell ALL: Evandro Bezerra, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Evandro Bezerra, a Hematology Specialist at the Ohio State University Comprehensive Cancer Center, sat down with Oncology Data Advisor to discuss his team...
Investigating Therapies Targeting Cardiovascular Health in MDS With Diego Adrianzen Herrera, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Therapies Targeting Cardiovascular Health in MDS: Diego Adrianzen Herrera, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Diego Adrianzen Herrera, a Malignant Hematologist at the University of Vermont Medical Center, about his study investigating the impact of hypomethylating agents on cardiovascular disease risk for patients with myelodysplastic syndromes (MDS). Dr. Adrianzen Herrera explains the study's results and how they can be used to design future research around treatments targeting cardiovascular health in MDS.  
Investigating Talquetamab Plus Pomalidomide in the MonumenTAL-2 Study With Jeffrey Matous, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Investigating Talquetamab + Pomalidomide in the MonumenTAL-2 Study: Jeffrey Matous, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Jeffrey Matous, MD, a Member of the Colorado Blood Cancer Institute in Denver, Colorado, presented his team's research and results of the MonumenTAL-2 trial...
Improving Diversity in Multiple Myeloma Clinical Trials With Craig Cole, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving Diversity in Multiple Myeloma Clinical Trials: Craig Cole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute, sat down with Oncology Data Advisor to share his passion for improving diversity in multiple myeloma clinical trials. He discusses the efforts that are currently underway to increase diverse accrual and the importance of raising awareness in order to address this issue both within the community and on a global scale.  
Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes With Claire Saxton, MBA
Keira Smith
Expert Analysis
Oncology Data Advisor® · Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes: Claire Saxton At the 2023 American Society of Hematology (ASH) Annual Meeting, Claire Saxton, Executive Vice President of Insights and Impact at Cancer Support Community, presented her team's study on communication that enables shared decision making in myelodysplastic syndromes (MDS). While there, she sat down with Oncology Data Advisor to discuss more about the results of the study and ways that health care professionals and patient advocacy groups can partner to ensure that clear and consistent messages are being delivered to patients with MDS so that they can be more informed and involved in their care.  
Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD   At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Brittany Ragon, Adult Leukemia and Transplant Specialist at Levine Cancer Institute, sat down with Oncology Data Advisor to discuss her pr...
Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma With Hans Lee, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Hans Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Hans Lee, the Director of Multiple Myeloma Clinical Research at MD Anderson, presented his team's research from the LINKER-MM1 study, which sought to eva...
CLL Society: Paving the Way for CLL Patients and Survivors With Brian Koffman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · CLL Society: Paving the Way For CLL Patients and Survivors With Brian Koffman, MD CLL Society is a patient-centric, physician-curated nonprofit organization that prioritizes patient education, advocacy, and research for the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) community. Dr. Brian Koffman co-founded the organization after being diagnosed with CLL in 2005, and he currently serves as Executive Vice President and Chief Medical Officer. He recently attended the American Society of Hematology (ASH) Annual Meeting to acquire the latest CLL research to bring back and disseminate to patients, and while there, he sat down with Oncology Data Advisor to share more about the educational and advocacy work that the society does, updates in CLL research being presented at the meeting, and how patients with CLL can become more involved and empowered in their treatment and care.  
Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting With David Andorsky, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented ...